Female Infertility Pipeline Guide, H1 2020

DUBLIN, April 22, 2020 /PRNewswire/ -- The "Female Infertility Pipeline Guide, H1 2020" has been added to ResearchAndMarkets.com's offering.

This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 19, 15, 1, 26, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
• The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

Companies Mentioned

• Adynxx Inc
• AlphaMab Co Ltd
• Amega Biotech
• Aprilbio Co Ltd
• Aptorum Group Ltd
• ARTham Therapeutics Inc
• ASKA Pharmaceutical Co Ltd
• Auritec Pharmaceuticals Inc
• Bayer AG
• Beijing Fogangren Bio-Pharm Tech Co Ltd
• Bharat Serums And Vaccines Ltd
• Bol Pharma
• Cadila Healthcare Ltd
• Chugai Pharmaceutical Co Ltd
• Context Therapeutics LLC
• Daewoong Pharmaceutical Co Ltd
• ElexoPharm GmbH
• Enteris BioPharma Inc
• Eurofarma Laboratorios SA
• Evestra Inc
• Evotec SE
• FemmePharma Global Healthcare Inc
• Ferring International Center SA
• Forendo Pharma Oy
• GeneScience Pharmaceuticals Co Ltd
• Genome & Co
• Glycotope GmbH
• Igenomix SL
• Igyxos SA
• Immunitor Inc
• Isifer AB
• Jiangsu Hengrui Medicine Co Ltd
• Kissei Pharmaceutical Co Ltd
• LG Chem Ltd
• Livzon Pharmaceutical Group Co Ltd
• Luye Pharma Group Ltd
• Mitsubishi Tanabe Pharma Corp
• Myovant Sciences Ltd
• Navad Life Sciences Pte Ltd
• Nippon Shinyaku Co Ltd
• NutriBand Inc
• Pangen Biotech Inc
• Park Active Molecules
• Philogen SpA
• Predictive Therapeutics LLC
• PregLem SA
• Richter Gedeon Nyrt
• Shanghai Jing Ze Biotechnology Co Ltd
• Shenzhen Salubris Pharmaceuticals Co Ltd
• SK Chemicals Co Ltd
• Suzhou JiSheng Pharmaceutical Co Ltd
• SYNG Pharmaceuticals Inc
• Takeda Pharmaceutical Co Ltd
• Temple Therapeutics BV
• TiumBio Co Ltd
• Trophogen Inc
• Union Therapeutics AS
• ValiRx Plc
• Viramal Ltd
• Xbrane Biopharma AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9n6kdz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/female-infertility-pipeline-guide-h1-2020-301045424.html

SOURCE Research and Markets